

Substitute Form PTO-1449  
(May 2007)U.S. Department of Commerce  
Patent and Trademark OfficeAttorney's Docket No.  
3800024.00324/1112USApplication No.  
10/590,119**List of Patents and Publications for Applicant's  
Information Disclosure Statement**

(37 CFR §1.98(b))

**U.S. Patent Documents**

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
/N.C./	AA	2010/0069379	03/18/10	Zhi <i>et al.</i>	514	230.5	11/13/09
/N.C./	AB	7,696,246	04/13/10	Zhi <i>et al.</i>	514	457	06/23/05
/N.C./	AC	7,727,980	06/01/10	Zhi <i>et al.</i>	514	215	01/31/06

**Foreign Patent Documents or Published Foreign Patent Applications**

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation Yes	Translation No
None								

**Other Documents (include Author, Title, Date, and Place of Publication)**

Examiner Initial	Desig. ID	Document
/N.C./	AD	Kapil <i>et al.</i> , "Phase I clinical trial of LGD-4033, a novel selective androgen receptor modulator (SARM)," 14th International Congress of Endocrinology, Kyoto, Japan, March 26-30, 2010, 1 page [poster presentation].
/N.C./	AE	Vadja <i>et al.</i> , "LGD-4033 builds muscle and bone with reduced prostate activity and may be beneficial in age-related frailty," Gerontological Society of America 62nd Annual Scientific Meeting, Atlanta, Georgia, Nov. 18-22, 2009, 1 page [poster presentation].

Examiner Signature /Nizal Chandrakumar/	Date Considered 09/25/2010
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	